UBR Box Domain Ligands for Blocking Substrate Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective ligands that can bind to the UBR box domain, which is crucial for regulating intracellular proteolytic pathways, leading to challenges in treating UBR-related diseases such as muscle loss and excessive protein degradation.
Innovation Solution
Development of small molecule compounds that specifically bind to the UBR box domain, inhibiting substrate binding and providing pharmaceutical compositions for treating UBR-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are designed to bind to the UBR box domain, then substrate binding is inhibited and protein degradation is suppressed, but the development of effective ligands with high binding strength has been lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular structures (changing chemical parameters) to optimize binding affinity to the UBR box domain. Multiple compound structures with varying substituents and molecular weights were synthesized to achieve high binding strength, directly addressing the lack of effective ligands.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that bind to the UBR box domain to prevent substrate binding. These compounds act as mediators between the UBR box domain and substrates, blocking the interaction that leads to protein degradation without directly modifying the domain structure.
2Adaptability or versatility
If ligands are developed to bind to the UBR box domain, then therapeutic benefits for UBR-related diseases can be achieved, but current technologies lack effective ligands
Solution Approach 1:
The patent develops compounds that can universally bind to the UBR box domain across different UBR proteins (UBR1, UBR2, UBR3, UBR5), providing broad therapeutic applicability. The ligands are designed to target the conserved UBR box domain structure, enabling them to inhibit multiple UBR-related degradation pathways simultaneously.
Solution Approach 2:
The patent creates synthetic small molecule copies that mimic the binding characteristics of natural substrates but with enhanced affinity and selectivity for the UBR box domain. These copied structures serve as effective ligands that replicate and improve upon natural binding interactions.
3Stability of the object's composition
If compounds are used to suppress substrate degradation, then protein stability is improved, but the compounds must achieve high binding strength to the UBR box domain
Solution Approach 1:
The patent employs preliminary action by designing compounds with pre-optimized structural features that facilitate high-affinity binding to the UBR box domain before administration. The molecular structures are预先 designed with specific functional groups and spatial arrangements that predictively enhance binding strength, ensuring effective protein stability protection.
Solution Approach 2:
The patent uses composite molecular structures combining multiple functional moieties (aromatic rings, heterocycles, substituent groups) to create compounds with enhanced binding properties. These composite structures leverage synergistic interactions between different molecular components to achieve the required binding strength for effective protein stabilization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds exhibit high binding strength to the UBR box domain, effectively suppressing substrate degradation and offering therapeutic benefits for conditions like muscular dystrophy, sarcopenia, and cancer cachexia.
Implementation Method 1
a compound that serves as a ligand that binds to the UBR box domain
Data Source
AI summary
The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.